Immunomodulating compounds and related compositions and methods

Abstract

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

1 .- 12 . (canceled) 
     
     
         13 . A method to control cytokine production in an individual, the cytokine being at least one of IL-1, IL-6, TNF-α, IL-17, IL-21, IL-23, the method comprising administering to the individual an amount of a zwitterionic polysaccharide effective to control production of the cytokine. 
     
     
         14 . The method of  claim 13 , wherein the cytokine is 11-17. 
     
     
         15 . The method of  claim 13 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA). 
     
     
         16 . A method to control an inflammation associated with production of at least one of IL-1, IL-6, TNF-α, IL-17, IL-21, IL-23 in an individual, the method comprising administering to the individual of a zwitterionic polysaccharide in an amount effective to control the inflammation. 
     
     
         17 .- 21 . (canceled) 
     
     
         22 . A therapeutic method comprising:
 orally or parenterally administering to the individual a pharmaceutical composition comprising a purified zwitterionic polysaccharide to an individual having an imbalanced profile of T-helper cells selected from Th1, Th17, and Treg cells, which imbalanced profile is associated with intestinal colitis.   
     
     
         23 . (canceled) 
     
     
         24 . The therapeutic method of  claim 22 , wherein the individual is suffering from inflammation; and the orally or parenterally administering comprises administering an amount of the zwitterionic polysaccharide effective to inhibit the inflammation. 
     
     
         25 . The therapeutic method of  claim 22 , wherein the zwitterionic polysaccharide is present in the pharmaceutical composition in an amount of from about 0.01 ug to about 1,000 ug. 
     
     
         26 . The therapeutic method of  claim 22 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA) or polysaccharide B (PSB). 
     
     
         27 . The method of  claim 16 , wherein the amount of the zwitterionic polysaccharide is from about 0.01 μg to about 1,000 μg. 
     
     
         28 . The method of  claim 16 , wherein the zwitterionic polysaccharide is a  B fragilis  capsular polysaccharide A (PSA) or polysaccharide B (PSB).